CSPC’s JMT101 Receives Breakthrough Therapy Designation in China

An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.

CSPC Pharmaceutical Group announced that its drug JMT101 has been granted Breakthrough Therapy Designation in China for treating advanced colorectal cancer. This designation, based on promising phase II clinical trial results, highlights JMT101’s potential to improve treatment outcomes for patients who have failed standard therapies, positioning it as a potential new standard for later-line colorectal cancer treatment.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on developing innovative drugs. It specializes in producing monoclonal antibodies and other pharmaceutical products, with a market focus on treating various types of cancer and other diseases.

YTD Price Performance: 69.49%

Average Trading Volume: 166,817,994

Technical Sentiment Signal: Buy

Current Market Cap: HK$93.14B

For an in-depth examination of 1093 stock, go to TipRanks’ Stock Analysis page.